Sagimet Biosciences Announces U.S. Phase 3 Trials for Acne Treatment Denifanstat
Sagimet Biosciences (NASDAQ: SGMT) stock surged 45.2% following the announcement of plans to initiate Phase 3 trials for its acne treatment denifanstat in the U.S. The decision comes after successful Phase 3 trials in China and is expected to begin in the second half of 2026. The move highlights the company's expansion into the U.S. acne market, which has 10 million sufferers.
Tickers: $SGMT
Topics: acne treatment biopharma clinical trials drug development Phase 3 trials